Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biotechnology company focused on precision T cell therapies and AI-enabled drug development, and its news flow reflects this dual emphasis on science and capital-efficient execution. Company announcements highlight progress across its ExacTcell™ platform, the Tevogen Bio therapeutic pipeline, and the Tevogen.AI analytics division, as well as financial and corporate developments disclosed through SEC filings.
Readers of the Tevogen news page can expect updates on clinical and scientific milestones, such as expanded HLA coverage for its investigational T cell therapy TVGN 489, completion of target identification for additional HLA restrictions, and preclinical work in areas including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers. The company also reports on recognition from industry and regional publications, intellectual property developments, and the evolution of its AI capabilities, including its PredicTcell™ model.
Tevogen’s news also covers financial and operational disclosures, including commentary around quarterly reports on Form 10-Q, non-GAAP metrics used by management, and statements on capital efficiency and cash burn. In addition, the company issues releases on corporate actions such as at-the-market equity programs and personal contributions by its founder and CEO to support facilities and community initiatives.
For investors and observers, following Tevogen news provides insight into how the company is advancing its precision T cell therapy programs, building out AI-driven target discovery, and managing its capital structure. Regular updates offer context on the company’s progress in infectious diseases, oncology, and neurology, as well as its stated focus on affordability and sustainable innovation.
Tevogen Bio, a clinical-stage specialty immunotherapy company, hosted its first post-public listing social engagement on May 31, 2024. The event, attended by patients, first responders, elected officials, and U.S. Congress members, highlighted the company's efforts in developing CD8+ cytotoxic T cell therapies for infectious diseases, cancers, and neurological disorders. Key attendees included several New Jersey mayors, U.S. Congressmen Josh Gottheimer and Robert Menendez, and first responder representatives. The discussion focused on understanding patient needs and exploring how Tevogen's model could reduce healthcare costs and improve outcomes.
Tevogen Bio has announced that its investigational immunotherapy, TVGN 489, remains effective against FLiRT strains of SARS-CoV-2, the dominant COVID-19 variants. TVGN 489, a Cytotoxic CD8+ T lymphocyte treatment, targets multiple conserved peptides across SARS-CoV-2 proteins, maintaining efficacy despite mutations. A phase I trial showed significant clinical improvement in high-risk patients, with virus reduction over 99% within 14 days and no significant adverse events. Tevogen plans further trials to assess TVGN 489's ongoing efficacy.
Tevogen Bio has reported its Q1 2024 financial results, indicating significant strides in its financial management and operations. The company eliminated $94.9 million in liabilities by converting promissory notes into common stock, resulting in a net income of $11.3 million. Operating cash usage was $2.1 million for the quarter. A new line of credit for up to $36 million has been secured, with an option for an additional $14 million contingent on stock price performance. Non-cash expenses were substantial, primarily driven by $25.2 million in stock-based compensation. Tevogen also incurred a one-time transaction cost of $7.5 million related to its recent business combination. The company remains committed to innovative product development and has made notable progress, including a successful proof-of-concept clinical trial for its T cell platform targeting Long COVID patients.
Tevogen Bio Holdings, a clinical-stage biotech company specializing in immunotherapy, has appointed William Keane as the Vice President of Strategic Initiatives. Keane, a former Chief of Police in Warren, NJ, and a graduate of the FBI National Academy, brings 35 years of leadership experience to the role. He will ensure compliance with regulatory guidelines and assist in procuring lab space to meet operational goals. Keane's appointment is expected to enhance Tevogen's strategic decision-making and further its mission in oncology, neurology, and virology therapeutics development.
Tevogen Bio Holdings Inc. has secured up to $50 million in financing to advance its ExacTcell platform and further clinical trials. The financing supports ongoing research and development efforts, including expanding clinical trials for TVGN 489 in oncology, neurology, and virology. The capital will also aid in starting new trials for virally induced cancers and multiple sclerosis. Dr. Ryan Saadi, Tevogen Bio's CEO, expressed gratitude for the support of existing shareholders, emphasizing the company's commitment to providing affordable T cell therapies for a wide range of patients.
Tevogen Bio announced its full-year 2023 financial results, highlighted its ExacTcell platform success, and upcoming operational objectives. The company aims to acquire a cell therapy manufacturing facility, expand clinical trials, and address Long COVID treatment. Tevogen Bio reported positive POC results for TVGN 489, showcasing safety and efficacy. The company is in discussions to secure manufacturing facilities, bolster research and development capabilities, and seek FDA approval for new clinical trials. Tevogen Bio is evaluating funding options to support growth plans, emphasizing favorable financing terms and equity control. Operating expenses for 2023 were $8.8 million, with significant liabilities converted to common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Tevogen Bio (TVGNW)?
